Status:
TERMINATED
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
Lead Sponsor:
Allergan
Conditions:
Irritable Bowel Syndrome
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts. Part A enrolled 213 pts dosed...
Eligibility Criteria
Inclusion
- Diagnosis of Irritable Bowel Syndrome
- Moderate or severe IBS pain
Exclusion
- Any other uncontrolled disease
- Pregnant or nursing females
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT00441766
Start Date
March 1 2007
End Date
February 1 2008
Last Update
January 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Orange, California, United States